Compliant Application of Endotoxin Control and Removal Kits for Cell and Gene Therapy Products

Background of Endotoxin Control for CGT Products

Cell therapy and gene therapy products typically involve intermediates such as plasmids, viral vectors, mRNA, or engineered cells. Their production processes are complex and involve many open steps, resulting in a relatively high risk of endotoxin introduction. Similar to recombinant proteins, the drug substance, intermediates, and finished products of CGT products often need to meet general endotoxin limit requirements. However, CGT products are relatively sensitive to effects on cell viability, vector titer, and gene expression, so the integrity of target components must be taken into account when removing endotoxin. Endotoxin removal kits are often used in such processes as process development tools or remedial measures, rather than directly replacing upstream aseptic control.

Positioning of Kits in Process Development

In plasmid purification, viral vector concentration, or culture medium treatment steps, process personnel can introduce an endotoxin removal step after intermediate purification to reduce the endotoxin level of the final product. A common practice is to use affinity chromatography or anion exchange prepacked columns to process samples with low endotoxin requirements. Because CGT products have complex compositions and contain nucleic acids, liposomes, or viral particles, different removal media may cause nonspecific binding or shearing effects on target components. Therefore, small-scale preliminary experiments to evaluate target component recovery, activity, and endotoxin removal efficiency are common steps in process development.

Key Points for Compliant Use and Validation

From a compliance perspective, when an endotoxin removal kit is used as a process consumable, its supplier should be able to provide material certification, endotoxin limit statements, and batch consistency documents. Users need to complete endotoxin removal validation based on the actual process, including endotoxin levels before and after removal, changes in critical quality attributes of target components, and reproducibility. If clinical sample preparation is involved, traceability and change management of kit components also need attention. It is generally required that validation data cover multiple independent batches and that endotoxin testing release specifications be established.

Common Issues and Risk Reminders

Some endotoxin removal media may release ligands or matrix shedding under low ionic strength or extreme pH conditions, affecting product safety. Therefore, relevant residual indicators should be monitored after use. At the same time, endotoxin removal should not be regarded as a "final safeguard" that can replace upstream aseptic processes and raw and auxiliary material control. In the CGT field, robust process design, closed system control, and supplier audits usually reduce overall risk more effectively than relying solely on endotoxin removal kits. Only when sample characteristics and the process window are clearly defined can an endotoxin removal kit be reasonably incorporated into the quality control system.